MedPath

Paquinimod

Generic Name
Paquinimod
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C21H22N2O3
CAS Number
248282-01-1
Unique Ingredient Identifier
HB76GLG27V
Background

Paquinimod is developed for the treatment of SLE (Systemic Lupus Erythematosus), which is an autoimmune disease. The disease affects mainly women of fertile age and progresses in flares with relatively symptom free periods in between. Current treatments of SLE are NSAID (nonsteroidal anti-inflammatory drugs), corticosteroids, antimalarians or cytotoxic drugs like for example Cyclophosphamide. The autoimmune attack affects several different organ systems and many patients suffer from serious secondary disease symptoms such as renal disorders as the disease progresses.

Associated Conditions
-
Associated Therapies
-
openpr.com
·

Systemic Sclerosis Clinical Trials 2024: EMA, PDMA, FDA

DelveInsight's 2024 report highlights over 50 companies developing 50+ therapies for Systemic Sclerosis, detailing drug profiles, clinical trials, and mechanisms of action. Key players include Eicos Sciences and Corbus Pharmaceuticals, with promising therapies like GS-248 and Lenabasum in development.
© Copyright 2025. All Rights Reserved by MedPath